Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Testosterone enanthate
Drug ID BADD_D02172
Description Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate. This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.[A31615] This testosterone derivative was first approved on December 24, 1953.[L8941] In 2017, about 6.5 million retail prescriptions for testosterone therapy were filled [L4659]. The majority of the prescriptions written were for injectable (66%) and topical (32%) testosterone products. As recent as 1 October 2018, the US FDA approved Antares Pharma Inc.'s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659]. As the first subcutaneous autoinjector product designed for testosterone replacement therapy, this innovative formulation removes transfer concerns commonly associated with testosterone gels and potentially reduces the need for in-office/in-clinic injection procedures that may inconvenience patients with frequent visits to the clinic [L4659].
Indications and Usage In females, testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal. It has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.[FDA label]
Marketing Status Prescription; Discontinued
ATC Code G03BA03
DrugBank ID DB13944
KEGG ID D00958
MeSH ID C004648
PubChem ID 9416
TTD Drug ID Not Available
NDC Product Code 0395-8150; 54436-275; 62991-2700; 63275-9938; 54436-250; 64025-0020; 48087-0137; 60870-0266; 0143-9750; 51552-1336; 43647-567; 54436-200; 22552-0014; 12875-9951; 49803-005
Synonyms testosterone enanthate | testosterone heptanoate | testosterone heptylate | Primoteston Depot | Testosteron Depot-Rotexmedica | Testosteron-Depot Eifelfango | Delatestryl | Testrin P.A. | Theramex | Andropository | Durathate | Testosteron-Depot Jenapharm
Chemical Information
Molecular Formula C26H40O3
CAS Registry Number 315-37-7
SMILES CCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acne23.02.01.001--Not Available
Aggression19.05.01.001--Not Available
Alopecia23.02.02.001--
Amenorrhoea21.01.02.001; 05.05.01.002--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anger19.04.02.001--Not Available
Anxiety19.06.02.002--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Azoospermia21.03.03.001--
Blood calcium13.11.01.041--Not Available
Blood chloride13.11.01.042--Not Available
Blood cholesterol increased13.12.01.002--
Blood gonadotrophin decreased13.10.03.001--Not Available
Blood phosphorus13.11.01.023--Not Available
Blood potassium13.11.01.032--Not Available
Blood testosterone decreased13.10.05.004--Not Available
Breast pain21.05.05.003--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Clitoral engorgement21.08.02.006--Not Available
Coagulopathy01.01.02.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages